DHA Levels Rose, but Cognition Did Not Improve in a Two-Year Trial
On October 23, 2026, BGNES reported that a Keck Medicine of USC trial published in eBioMedicine found no cognitive benefit from DHA supplementation over two years. ScienceDaily had reported the study's lack of benefit on October 22, 2026.
How the researchers tested DHA
According to the BGNES account, the randomized trial enrolled 365 adults aged 55 to 80 who were considered at increased risk of Alzheimer's disease. Participants rarely ate fish. Within the study population, 47% carried APOE4, a genetic variant associated with higher Alzheimer's risk.
Participants were assigned to receive either 2,000 mg of DHA daily or a placebo. That amount describes the research intervention, not a recommendation for readers. The trial followed participants for two years.
The researchers assessed more than whether people took the supplement. They measured DHA in cerebrospinal fluid to assess delivery to the central nervous system. They also used cognitive tests and imaging to examine whether supplementation produced a meaningful difference compared with placebo.
Those measurements addressed separate questions. The fluid measure tested whether DHA reached the intended biological system. Cognitive testing and imaging assessed whether that delivery was accompanied by better thinking performance or protection against hippocampal atrophy.
For men reading about brain health after 45, that distinction is worth keeping in view. A supplement can meet a biological target without producing the outcome that matters to the person taking it. This trial allowed researchers to compare those two parts of the claim rather than treating them as interchangeable.
How the delivery result compared with cognitive outcomes
The BGNES report describes three central findings:
- DHA delivery increased. After six months, cerebrospinal-fluid DHA in the supplement group had risen by an average of 17%. The report interpreted this as evidence that the supplement reached the central nervous system.
- Cognitive performance showed no advantage. At two years, participants assigned to DHA did not perform better on cognitive tests than those assigned to placebo.
- Imaging showed no prevention of hippocampal atrophy. Supplementation did not prevent the shrinkage measured in that part of the brain.
The first result is a biological delivery finding. The other results concern the benefits the intervention was intended to produce. The supplement changed a brain-related nutrient measure, but that change was not accompanied by better reported cognitive or imaging outcomes.
A higher marker is not the same as better memory
A biomarker is a measured biological sign. Here, the reported marker was DHA in cerebrospinal fluid. Its increase answered a useful question about delivery, but it did not establish that participants remembered more or performed better on other thinking tests.
The comparison with placebo is central to interpreting the result. The relevant question was not simply whether DHA levels rose among people taking DHA. It was whether the supplement group did better on the outcomes being tested.
This is a useful standard for reading other brain-health claims. Evidence that a substance reaches a target should be identified as delivery evidence. Evidence that people think or function better needs to come from measurements of those outcomes.
A plausible mechanism still needs a successful outcome
BGNES identified Hussein Naji Yassine as director of USC's Center for Personalized Brain Health. He said omega-3s play a role in forming connections between brain cells. He also said the findings did not support fish-oil supplements as a preventive measure against Alzheimer's disease.
Those statements address different levels of evidence. A nutrient's role in brain biology provides a reason to study it. A trial tests whether supplying more of that nutrient produces a benefit under the conditions studied.
Here, the reported rise in DHA did not carry through to the cognitive and imaging results. The value of the trial lies partly in making that gap visible. It asks readers to judge the intervention by its measured outcomes rather than by the appeal of its biological explanation.
Why the findings need a narrow reading
This was a two-year test of one DHA intervention in a selected population. Its findings do not establish the effects of every omega-3 product across all ages or health conditions. They also do not show that DHA never helps cognition in any setting.
The BGNES report explicitly separates high-dose DHA supplementation from eating fish. The findings do not establish that omega-3 fatty acids are unnecessary or that fish has no health benefits. A capsule intervention and a broader eating pattern are different research questions.
The accessible account does not provide the paper's full methods, confidence intervals or detailed outcome estimates. That limits assessment of the size and precision of the differences between groups. The defensible conclusion is the one reported: no cognitive-test advantage and no prevention of hippocampal atrophy.
Yassine also suggested that omega-3s might work differently within a broader dietary pattern such as a Mediterranean-style diet. That was a research interpretation, not a finding tested by this DHA trial. His comments about exercise and sleep were broader lifestyle advice rather than results of the placebo comparison.
How to put the findings into a brain-health perspective
The practical lesson is to keep the purpose of a supplement separate from the evidence supporting that purpose. For someone interested in preserving memory, a higher DHA marker is not a substitute for a demonstrated cognitive benefit. This trial provides a direct example of why those claims should be assessed separately.
For men already using a supplement, the result is not a reason to stop something prescribed for another purpose. Individual use should be discussed with a qualified clinician. That conversation can keep the reason for taking it separate from assumptions about memory protection.
Yassine's broader advice highlighted regular exercise, good-quality sleep and balanced eating. Those subjects belong in a discussion of staying mentally sharp, but they should be assessed through their own evidence. They should not be presented as benefits established by this supplement experiment.
For related reading, Everfitguys examines research on exercise and cognitive aging and how sleep efficiency relates to thinking performance. Its coverage of dietary patterns and cognitive measures addresses another part of the wider brain-health discussion.
A useful way to assess the next supplement headline is to ask what actually improved. Was it a nutrient level, a cognitive test result or a clinical outcome? Keeping those answers separate makes the evidence easier to judge without turning every promising mechanism into a purchasing decision.
What this changes: this trial challenges confidence in stand-alone DHA supplementation for brain protection rather than establishing a new best practice for preventing Alzheimer's disease.
How Everfitguys helps
A rise in a brain-related nutrient marker can be mistaken for better memory when attention stops at the biology. Everfitguys is a research-led editorial publication for men 45 and older concerned with mental sharpness. Its focus is clear explanation of healthy-aging evidence without turning uncertain findings into medical advice.
Sources
Stay sharp
Get stories
The best writing on craft and life, delivered once a week. No noise, just the good stuff.
